Psychoactive medication for children and adolescents: orientation for parents, guardians, and others by Children and Adolescents' Psychoactive Medication Workgroup. et al.
 
  
 
Massachusetts Department of Mental Health 
Barbara A. Leadholm, M.S., M.B.A., Commissioner 
 
 
 
 
 
Psychoactive Medication for Children and Adolescents: 
Orientation for Parents, Guardians, and Others 
 
 
 
 
 
The Children and Adolescents’  
Psychoactive Medication Workgroup 
 
 
 
 
 
 
 
 
 
 
 
 
Division of Child and Adolescent Services 
Office of Clinical and Professional Services 
 
February 2002 
Revised July 2003 
Revised January 2005 
Revised September 2007 
 
 
 
 
 
 
 2 
 
 
 
 
PREFACE TO 2005 REVISION 
 
This revision reflects new scientific data, policy developments, and feedback from 
users of the first version.  Appreciation is expressed to Manuela da Costa, of DSS, 
and Dr Virginia Merritt. 
 
       Gordon Harper, MD 
       Medical Director 
       Child & Adolescent Services 
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       Gordon Harper, MD 
Medical Director 
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PREFACE 
 
 
This booklet presents principles for the use of psychoactive medication in children 
and adolescents.  It offers information about medication treatment.  It does not 
recommend specific medications or doses.  The booklet was developed by a group 
convened by the Division of Child and Adolescent Services of the Massachusetts 
Department of Mental Health.  The group included representatives of the 
Department of Social Services (DSS), the Division of Medical Assistance, the 
Juvenile Court Clinic, the Massachusetts Behavioral Health Partnership, the New 
England Council of Child Psychiatry, the Parent Professional Advocacy League, and 
representative hospitals and health care organizations.  Participants are listed in 
Appendix VII, Members of Working Group.  
 
The Working Group expresses appreciation for review of the document and helpful 
suggestions from other colleagues, notably Drs. Joseph Biederman, Ronald 
Steingard, Ed Wang, and Linda Zamvil, and Bernadette Drum, BSN, JD. 
 
Gordon Harper, MD 
Chairman  
Children and Adolescents’ Psychoactive Medication Workgroup 
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I. INTRODUCTION 
 
A.  Childhood Disorders: How common?   
 
Eleven percent of children and adolescents in the United States ages 9 to 17 are 
estimated to have a diagnosable mental or addictive disorder with significant 
functional impairment (Surgeon General’s Report on Mental Health, 2000).  
Consistent with this estimate, 4 million youths may suffer from a major mental 
illness and have significant impairments at home, at school, and with peers. Those 
with impaired development are at greater risk.  Abuse or neglect, suffered by 
three million children and adolescents each year in the United States, is a major 
risk factor for later mental disorder. 
 
 
B.  Psychoactive Medication for Children and Adolescents: Recent 
changes 
 
Children and adolescents with serious emotional disturbance are receiving 
psychoactive medication more often than in the past.    
 
Several factors have contributed to this increase.   One factor is scientific 
progress; another is changing attitudes towards children and adolescents’ mental 
health, such as: 
 
• advances in our understanding of how the brain works.  We now recognize 
that the brain functions differently in children and adolescents with mental 
disorders; 
• evidence that many children with symptoms grow up to have disorders as 
adults; 
• greater recognition of child and adolescent mental health needs and increasing 
readiness to define those needs in terms of brain functioning; and 
• the availability of a wider range of psychoactive medications. 
 
In addition, child and adolescent mental health services have changed: 
 
• Children and adolescents with serious emotional disturbance are no longer 
treated only in hospitals, but often in foster homes and community residences, 
facilities that have not historically treated children and adolescents with serious 
behavioral symptoms.  Children and adolescents are hospitalized for shorter 
lengths of stay, resulting in pressure to use interventions that are likely to have 
a rapid effect, such as medication. 
 
C.  Psychoactive Medication for Children and Adolescents:  How do we 
know what to recommend? 
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Medication practice in children and adolescents, like other areas of medical 
practice, is based on clinical experience and controlled clinical trials.  “Evidence-
based medicine” includes both kinds of evidence. 
 
While controlled clinical trials in children and adolescents are becoming more 
common, most medication practice in children—in general medicine as well as in 
mental health—is based on clinical experience and individual clinicians’ judgment.  
This is because drug development for children and controlled clinical trials to 
evaluate those drugs are much more difficult to do than for adults.  Therefore, 
most pharmacological research is done with adults.   
 
 
D. The FDA, “approved” and “off-label” uses, black box warnings, and 
clinical judgment 
 
The Food and Drug Administration (FDA) relies on information from controlled 
clinical trials to approve new medications.  Because there are very few controlled 
clinical trials with children, the FDA has not approved the vast majority of 
medications for use with children.   When medications are used for indications or 
populations (such as children and adolescents) that the FDA has not approved, 
such use is called “off-label.”   
 
In addition to approving medications, the FDA sometimes requires that warnings 
(so-called “black box warnings”) be printed along with medication information that 
is included when a prescription is filled.  (See sections IV.B. and V.A., for 
discussion of the “black box warning” regarding antidepressant medications.) 
 
Clinicians prescribing for children and adolescents must exercise caution, 
considering the physical and emotional development of the child, any neurological 
or developmental deficits, possible interactions with other medications, and the 
risk that children or adolescents may try other drugs or alcohol. 
 
Children’s and adolescents’ responses to medication are difficult to predict.  A child 
may not respond to a medicine that has been helpful to others, or may require a 
higher or lower dose than usual.  Another child may have side effects at a dose 
that most can tolerate well.  Genetic differences may account for much of this 
variability. 
 
 
E.  Personal Representatives: Their responsibilities 
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Whenever a medication is recommended for a child or adolescent, those with 
responsibility for them, called Personal Representatives,1 should raise questions 
like these: 
 
• How do I assess medication recommendations made by a clinician? 
• With limited data about possible benefits and risks, particularly in growing 
children and adolescents, on what basis do clinicians make recommendations? 
• How should I decide to authorize treatment? 
• How can clinicians inform me of my choices?   
• How can I get the best information? 
 
This booklet responds to these questions.  In doing so, we hope to contribute to 
one of the goals in the Surgeon General’s Action Plan for Children’s Mental Health: 
to “make available information on effective prevention and treatment 
interventions...”  
 
 
F.  New Knowledge, New Ways to Help Children and Adolescents 
 
New developments in pediatric psychopharmacology give us new opportunities to 
help children and adolescents.  Child psychiatrists and other clinicians are learning 
more from organized clinical trials and from clinical experience.  
 
 
G.  Promoting Access 
 
Children and adolescents are referred for pharmacological treatment from many 
places.  They come from schools and pediatricians’ offices; special education; child 
welfare and child protection (including DSS); court, probation, or the Department 
of Youth Services (DYS) (where 50 percent of youths have been exposed to abuse 
or neglect); and mental health settings.  Referral is more likely when symptoms 
persist or are thought unlikely to respond to psychosocial interventions alone. 
 
But most children with serious emotional disorders are not getting the help they 
need.  Youth from ethnic and racial minorities encounter barriers in seeking and 
receiving good treatment, as the Surgeon General has reported.  Barriers include 
stigma (that is, prejudice against those with mental illness), mistrust, cost, clinical 
bias, and cultural suspicion of people with mental illness.  
                                                 
1  The US Health Insurance Portability and Accountability Act (HIPAA) defines the person who is 
legally authorized to make health care decisions as a "Personal Representative."  The Personal 
Representative may be the minor's parent, a court-appointed guardian (with scope to cover health 
care decisions) or an entity (e.g. DSS or DYS).   
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We hope information in this booklet will promote access to care for children who 
are challenged by emotional and mental troubles. 
 
 
H.  This Booklet  
 
• acknowledges that the field of pharmacotherapy for children and adolescents is 
growing rapidly;  
• provides general information about psychoactive medication for children and 
adolescents; 
• offers principles of good care; and 
• describes areas of ongoing controversy. 
 
This document does not indicate which medication should be used for a given kind 
of mental trouble; that information is provided in available resources like Connor 
and Meltzer (see references, at VI below).  Nor does it recommend particular 
medications or doses.  
 
 
 
II  CHILDHOOD AND ADOLESCENT MENTAL HEALTH – AN OVERVIEW 
 
A.  How children grow:  Differences in development 
 
Children and adolescents vary in many ways as they grow up.  Some are taller, 
some shorter.  Some eat voraciously and with pleasure; others just eat.  Some 
read early on their own, others later and with effort.  For some, puberty comes 
early, for others, later. 
 
Though everything changes with time, some children “take to” a developmental 
stage early or easily, others later or with difficulty. 
 
Similarly, differences also occur in behavioral and emotional development.  For 
instance, some children are calmer, some more restless.   Some are more clingy, 
others more independent.  For some, mood varies little; others have periods when 
they feel down or frankly depressed.  Some are barely ruffled by upsets and 
challenges; others “lose their temper,” as we say, sometimes for extended times.  
 
Diagnostic statements about children are always made against the background of 
normal development and the spectrum of abnormal development. 
 
In addition, some diagnoses refer to conditions that are long-lasting (chronic 
conditions) and those that are short-lived or acute. 
 11 
 
B.  When do “differences” amount to “disorders?” 
 
Children at the extreme of any continuum are said to have “conditions” or 
“disorders.”  Doctors and other students of child development have to define how 
many symptoms it takes to “make” a “condition” or “disorder.”   
 
Psychiatrists have written a manual, the American Psychiatric Association’s 
Diagnostic and Statistical Manual, 4th edition (DSM-IV), with the criteria for all of 
the so-called “mental disorders.”  These diagnoses are used for classifying the 
mental disorders that adults, children, and adolescents have.  Most of the 
“disorders” fall in categories (Anxiety Disorders, Mood Disorders, Psychotic 
Disorders, etc.) derived from adult psychiatry; these disorders do not always fit 
neatly with the troubles children have.  Some of the “disorders” (like Attention-
Deficit/ Hyperactivity Disorder, Tic Disorders, Conduct Disorders, Developmental 
Disorders, and Learning Disorders) usually arise in childhood or adolescence. 
 
Talking about “disorders” may sound odd to parents, teachers, and others who 
are accustomed to describe children’s troubles in terms of differences in 
development. 
 
Children who do not have all the features of a disorder, as defined by the DSM-IV, 
are called “subthreshold.”  They may still need help, even if they do not meet “all 
the criteria.”  And defining any child’s trouble usually requires more than a DSM 
diagnosis (see below, III-A). 
  
Children and adolescents with an emotional and behavioral trouble need a careful 
assessment.  Appropriate help usually includes several kinds of intervention, not 
just medication.  Such help is called multimodal treatment. 
 
C.  What can medication help with? 
 
Medication may help with many problems, but not with everything.   Medication 
may help with disturbances of mood (depressed, elevated mood [hypomania or 
mania] or unstable mood), disturbances of attention (attention deficit-
hyperactivity disorder), anxiety symptoms including compulsions and flashbacks 
and other consequences of trauma, some impulse control problems, and confused 
thinking and perceptions. 
 
Medication will not “bring up to age” a child or adolescent with delayed 
development.  Medication might, however, help with specified symptoms.  
Medications will not take away the disturbed language and ways of relating seen 
in children and adolescents with autism or other pervasive developmental 
disorders.  But medication might help with associated problems like aggression, 
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obsessive-compulsive behavior or scattered attention.   Medication will not help a 
child or adolescent who has a problem telling the truth.  But if lying is a symptom 
of a major depression, antidepressant medication might help with the depression.  
Medication will not help with “normal” childhood sadness but may help with 
clinical depression. 
 
Are we treating “symptoms” (specific problem behaviors) or “disorders” 
(diagnoses)?  This question can be puzzling; the difference between symptoms 
and disorders can be confusing. Parents bring their children and adolescents for 
help with symptoms, such as poor school performance, irritability, tics, and 
depressed mood.  But the same symptoms may come from many different 
disorders, each pointing to differences in brain chemistry and requiring different 
medication.  Because choice of medicine should be guided by a diagnosis, doctors 
usually diagnose a disorder before recommending a trial of medication.   
 
For instance, a child or adolescent’s poor attention may be associated with 
attention deficit-hyperactivity disorder (ADHD), major depression, psychosis, 
metabolic disorder, or traumatic brain injury.  The indicated medicine will be 
different with each disorder.  Irritability may occur in children and adolescents 
with brain injury or metabolic disorder, as well as ADHD, depression, Tourette 
Syndrome, or an adjustment disorder. 
 
But while a specific diagnosis may point to disorder-specific treatment, it is not 
always possible to base clinical practice on diagnosis alone.  Psychiatric diagnoses 
are “conventions,” that is, agreements among physicians about ways to classify 
people’s troubles.  These conventions, though shared by doctors and endorsed by 
insurance companies, differ from the ways that families, and whole cultures, talk 
about their children’s behavior.  Professionals must respect a family's ways of 
telling the story of a child's trouble, in addition to using the “scientific” tools of 
diagnoses from the Diagnostic and Statistical Manual of the American Psychiatric 
Association (the DSM). 
 
In addition, DSM diagnoses “fit the patient” less well in child psychiatry than with 
adults; to adequately describe their adaptive troubles, many children and 
adolescents are given multiple DSM diagnoses.  Future research may refine our 
present diagnoses, add new ones, or encourage use of different approaches to 
assessment of children and adolescents (e.g., dimensional diagnosis).  In the 
meantime, clinicians are trying to help children and adolescents with specific 
symptoms, the targets of prescribed medications. 
 
Parents, guardians and professionals must keep in mind both symptoms and 
diagnoses and the languages that parents, children and adolescents use to talk 
about their troubles. 
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III. PRINCIPLES OF PRACTICE 
 
A. Assessment 
 
1.  A comprehensive assessment:  What does it mean? 
 
Any pharmacotherapy should be preceded by assessment that is individualized, 
careful, and as comprehensive as necessary. 
 
Assessment of children and adolescents is complicated by: 
 
• the variety of symptoms in childhood.  Categorical diagnoses (like those in 
DSM-IV) may not fully capture the variety of symptoms in children and 
adolescents.  As a result, children and adolescents often receive multiple 
diagnoses. Even so, families may still feel that the doctor’s “language” doesn’t 
fit their own ways of thinking and talking about the troubles of their child or 
adolescent. 
 
• the way symptoms in children and adolescents change over time.  In some 
conditions, symptoms remain stable for years.  In other conditions, symptoms 
continually change.  In still others, there are periods of good functioning 
interrupted by intervals of symptoms, even serious symptoms. 
Medication treatment must be part of a comprehensive plan based on a 
comprehensive assessment which must include the child or adolescent, the family, 
and relevant aspects of their world.  Data should be gathered in interviews with 
the child or adolescent and parents (or, absent parents, other caretakers) and 
from collateral sources (e.g., teachers, protective service workers).  In many 
situations, collateral data (from teachers or protective service workers) are 
essential.  Previous medical records should be reviewed.  Discussion with the 
child’s or adolescent's primary care physician is indicated.   
 
Assessment of the child or adolescent should identify: 
 
• presenting symptoms, including the child’s or adolescent’s own words for 
symptoms; 
• current level of functioning;  
• developmental history;  
• medical history, including history of substance use, previous treatment history, 
current psychological examination; and  
• any history of neglect, abuse, molestation, or other trauma. 
 
2.  Family, Peers and School, Pediatric Liaison, Psychological Testing 
 
Assessment of the family should include: 
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• family history of mental illness;  
• assessment of current functioning and stressors;  
• assessment of attitudes toward the child or adolescent’s symptoms and needs, 
including the family’s or their culture’s ways of describing the child or 
adolescent; and  
• any current or past protective needs.   
 
Assessment of the child’s world should describe how the child or adolescent 
functions with peers and at school.  Assessment should identify, for child or 
adolescent and family, strengths as well as weaknesses.  Assessment of children 
and adolescents should include description of their attitudes to their symptoms 
and readiness to participate in treatment. 
 
Medical assessment of the child or adolescent should assess: 
 
• general health and development,  
• well-child care, and  
• possible contributing medical factors.   
 
Medical assessment should include a physical examination.   
 
A call to the primary care physician will provide much of this information and 
establish connections between physicians. 
 
A more detailed assessment should be offered to children and adolescents with 
severe symptoms, chronic symptoms, or potential for harm to self or others, and 
to those for whom ordinary treatment—including treatment with several 
medications or repeated hospitalizations—have not brought relief.  More intensive 
assessment includes more extensive history from the child or adolescent, family 
members, and other treating professionals current or past.  More intensive 
assessment may include consultation from specialists in child psychiatry, 
neurology, neuropsychology, pediatrics, child development, child abuse and 
neglect, and treatment systems. 
 
Psychological testing should be considered for some children and adolescents to 
further clarify the child’s or adolescent’s thoughts and feelings, intellectual 
capacity, and possible learning problems. 
 
3.  Interviews, Rating Scales: Using both 
 
Assessment relies on clinical interviews.  In addition, structured methods (like 
rating scales, questionnaires, and tests) may be used.  Commonly used rating 
scales include the Child Behavior Check List (CBCL), also known as the Achenbach 
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Rating Scale, and the Beck Depression Inventory (BDI), or its pediatric version, 
the Child Depression Inventory (CDI).  All data from rating scales must be 
interpreted by a clinician.  All assessments must recognize the culture of the child 
or adolescent and family.  Assessment and treatment must be appropriately 
documented and monitored. 
 
4.  Providing more than a DSM diagnosis 
 
Assessment should provide more than a categorical (DSM) diagnosis.  Those 
assessing children and adolescents should: 
 
• consider the adaptive perspective, meaning that the child’s or adolescent’s 
symptoms represent his or her best efforts to cope; 
• use a developmental perspective, locating symptoms in the context of longer-
term development and adaptation; 
• distinguish between transient and longer-term conditions; 
• balance accurate description of problems with the identification of strengths 
and the fostering of hope; and 
• balance early detection to facilitate intervention with the risk of inaccurate 
diagnosis and adverse effects of labeling. 
 
5.  Cultural assessment 
 
Clinicians should assess the culture of the child or adolescent relative to their own.  
Clinicians should acknowledge differences in experience or cultural background 
and consider what knowledge, skills and attitudes they need in order to provide 
care.  The clinician should understand how values, beliefs, customs, language and 
communication style influence the perception and expression of mental distress, 
how they shape help-seeking behavior and how their own backgrounds affect the 
way they hear and respond to children’s troubles.  The goal is make a partnership 
or alliance in order to help the child. 
 
B. Planning and Contracting for Treatment  
Contracting for treatment requires time, attention and discussion.  
Assessment precedes treatment planning.  In assessment process, the clinician 
specifies target symptoms and goals, selects a medication for initial use and 
schedules visits for evaluating progress.  The clinician then recommends 
treatment, including medication, to the child or adolescent, parent or guardian.  
Informed consent can then be sought.  
1. Defining Problems, Target Symptoms, and Goals 
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Assessment identifies relevant diagnoses and treatable symptoms.  Diagnoses may 
help clarify the nature of the child’s or adolescent’s problems and predict their 
response to treatment.   
 
Treatment is directed to target symptoms, such as anxiety, insomnia, poor 
concentration, or impulsiveness.  It is best to avoid using non-descriptive terms 
like “acting out” or “behavioral issues.”  The target symptoms selected should 
reflect the priorities of the child or adolescent, his or her family, and others (such 
as teachers or residential staff), in terms of what symptoms are most in need of 
improvement.  Target symptoms are not diagnoses; a given symptom might be 
seen in a variety of disorders. Indeed, a single diagnosis or disorder may 
contribute to a number of different symptoms.  A diagnosis is one context for a 
symptom, to be taken into consideration along with other contexts, such as 
presence of developmental disabilities, medical illness, history of abuse, or 
disruption of care-taking. 
Stating target symptoms in child-friendly language helps the clinician develop a 
treatment alliance with child or adolescent, family, and others.  For instance, a 
child may prefer to say, "I get really down and feel like dying," rather than, "I 
have depression with suicidal ideation."  Each party to the treatment should state 
what he or she hopes medication will do.  Each should be helped to understand 
what changes may realistically be expected.  Defining target symptoms provides a 
basis for judging the success of the treatment. 
Goals such as improved school performance or peer functioning are too broad to 
be specific targets for pharmacotherapy.  But such goals may help to clarify how 
medication can help—for example, by improving concentration or reducing social 
anxiety.  Distinguishing between improvement (or lack of it) in target symptoms 
and progress towards overall goals (or lack of it) can help in defining how 
medication can contribute to overall progress. 
Emergent side effects requiring treatment (like acute dystonias, activation on 
antidepressants (see section V.C.) or Parkinsonian symptoms) should be 
anticipated in the treatment plan.  When they occur, whether anticipated or not, 
they must be treated promptly. 
2. Selecting Medications 
A medicine will be recommended to the parent or guardian (usually with the 
assent and participation of the child or adolescent, according to their 
developmental level) considering:  
a) the class of medicines likely to be effective in treating the disorder;  
b)  the actions and side effects of individual medicines within that group; 
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c) the likely effects of the medicine on the target symptoms;  
d) likely side effects or potential toxic effects; and  
e) any available data regarding family members’ responses to this or similar 
medications.  
The recommendation should reflect the doctor’s judgment as to the best 
medication in general and the preferences of child or adolescent and family as to 
target symptoms and side effects.  Physicians should mention medications other 
than the one recommended and discuss with all parties what alternatives might be 
considered if the first agent is not effective. 
It is best to begin treatment with a single medication.  If a single medication 
proves to be effective, the response can be attributed to that agent and the child 
or adolescent will have been exposed to less risk of adverse effects.  If treatment 
with a single agent is ineffective, then it is appropriate to try a different single 
agent or to add an additional medication. 
3. Planning Treatment and Monitoring 
Monitoring 
Having selected a specific medication, the doctor, child or adolescent, family, and 
others should share their expectations.  Questions include the following: 
• How soon should the child or adolescent (and other observers) expect to see 
benefits from taking the medicine? 
• What side effects should be expected, and when?  What are the most common 
side effects?  Which are potentially the most serious? 
• What should the child or adolescent or family do if they notice side effects or 
other unexpected effects? 
• Who should look for indicators of progress or adverse effects and how?  Will 
monitoring include any formal assessment such as checklists or rating scales? 
• How will dosage adjustments be made and in response to which indicators of 
progress or lack of progress? 
• Will laboratory or other medical tests be called for?  If so, how and when 
should they be done? 
• How frequently should follow-up visits take place?  In response to which 
circumstances should more frequent or urgent visits be scheduled? 
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• Which medical problems might affect the use of the medication? 
• What symptoms might be expected when the medicine is stopped? 
• Are interactions likely between this medication and others, including alcohol or 
illegal substances, that the child or adolescent may be taking? 
• How will compliance with taking the medication be assessed, monitored, and 
assured? 
• Is there a risk of abusing this medication or of developing dependence? How 
will this risk be managed? 
Anticipating problems 
In treatment planning one must anticipate a course of action if the medicine does 
not seem or no longer seems to be effective.  Acknowledging this possibility at the 
start of treatment helps prevent disillusionment and increases the chances of 
continuing collaboration.  If all have agreed on target symptoms, on how to 
measure progress, and on the expected time course, then the doctor, the child or 
adolescent, the family and others will know when and how to consider 
alternatives.  Explicit planning also decreases the risk that an ineffective agent will 
be continued longer than appropriate because of unreasonable initial optimism.   
Seeking consultation 
The use of expert consultation should be considered if treatment is ineffective.  
Especially when the prescribing clinician is not a specialist in the treatment of the 
child's problems, it is useful to be prepared early on to seek consultation from 
someone with more experience.  The need for consultation may also arise when 
the child or adolescent or his or her family comes from a cultural background 
markedly different from that of the clinician. 
4.   Informed Consent 
 
Obtaining informed consent completes treatment contracting. Consent should 
reflect the elements outlined above.  The record should document who gives 
consent; what information is provided; and how, when, where and to whom 
consent is given.   
Who 
Typically, for children and adolescents under age 18, medical treatment, including 
psychoactive medication, must be authorized by the parent or guardian.  Except 
as noted below, there is no legal requirement that a minor child or adolescent give 
consent or “assent” (that is, implicitly consenting by taking the medicine) to 
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treatment.  Nonetheless, good clinical practice requires that doctor, parent, and 
others take account of the child’s or adolescent’s understanding of and attitude 
toward the treatment and that they gain as much assent as the child or 
adolescent can give.  The appropriate degree of autonomy to afford the minor 
varies with age, the type and degree of disability, the parent’s attitude, and the 
urgency of the treatment.  In some agencies, some minor children and 
adolescents are explicitly authorized to refuse psychiatric medication.  For 
example, the Department of Youth Services requires both parental consent and 
child or adolescent assent to medication, as youths in the DYS take their own 
medicine when given it by a staff person.  
An adolescent 18 or older must give consent to his or her own treatment. Certain 
adolescents below 18 (emancipated minors and so-called mature minors) also may 
consent to their own treatment.  “Emancipated minor” is defined by statute.  The 
designation of “mature” minor is a clinical decision based on two criteria: the 
ability of the minor to make an informed decision and the potential harm of 
informing the minor’s parents or guardian of the decision.  This concept is most 
often used in sexual or reproductive health care but may also be relevant when a 
parent and or adolescent disagree on a recommended medication treatment.  
Court endorsement of clinicians’ designation of the minor as emancipated may be 
sought but is not required. 
Some children and adolescents require special consent.  DSS caseworkers consent 
to “routine treatment” for children and adolescents in the custody of DSS, but not 
those in voluntary DSS care or committed to the department on a “Child in Need 
of Services,” or CHINS, petition.  But by DSS regulation, the prescription of 
antipsychotic medication is considered to be “extraordinary treatment,” requiring 
explicit court authorization (following a “Rogers petition”).  Children and 
adolescents in the joint legal custody of parents who disagree about treatment 
may require court assistance to establish authority to treat. 
What 
 
Informed consent should specify the child’s or adolescent’s condition and the 
proposed treatment.  A DMH policy (96-3R) provides relevant language: Clinicians 
must “disclose (to the patient and/or their legal guardian)… the significant medical 
information (as of 2003, “protected health information”)… that is material to an 
informed decision by the patient as to whether or not to undergo a proposed 
treatment.” The required information includes:  
• indications and target symptoms;  
• risks of the recommended medication (including significant, common, and 
possibly serious or life-threatening side effects);  
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• reasonably expectable benefits of treatment;  
• expectations of the course of illness without treatment;  
• reasonable alternatives to treatment;  
• expectations about results of interruptions in treatment; and  
• expectations concerning the monitoring of treatment. 
 
How 
 
To consent to medical care, a person (or his or her parent/guardian in the case of 
a minor) must be competent.  Individuals are presumed competent to make 
informed decisions unless they are “legally” incompetent (as are children and 
adolescents under 18), or unless a judge has found them to be incompetent, for 
instance in a guardianship proceeding.  The decision for or against treatment must 
be a voluntary one, made without undue influence from others; it must be based 
on a rational ability to understand facts as presented. A decision to forego 
treatment may or may not be in the person’s best interests, as seen by an 
outsider.  Although such decisions are sometimes called “irrational,” they are valid 
as long as the person is competent to make the choice.  For instance, a refusal of 
treatment based on religious beliefs may not be rational to another person but 
may still be competent.  The decision must also be adequately informed, as 
detailed above.   
 
The medical record needs to document the consent process, including who 
participates, what information has been conveyed, any concerns that may have 
arisen, and the final giving of consent for the treatment itself.  Standardized 
signature forms may help in documentation, especially if such forms specify the 
elements noted above.  Generic consent forms are neither necessary nor sufficient 
documentation for the giving of informed consent. 
When 
Consent for treatment must be obtained before treatment is begun, unless the 
treatment is considered to be an emergency (see below).  If treatment is 
undertaken as an emergency, consent must be obtained as soon as possible; 
treatment cannot continue beyond the emergency without consent.  New consent 
must also be obtained whenever a different medication is introduced and 
whenever there is any material change in the circumstances of treatment.  Such 
changes include the emergence of side effects, the development of a relevant 
medical problem, or other developments affecting risk and benefits.  Consent for 
treatment is not a one-time event but rather a process of ongoing discussion with 
a parent or parents, consenting child or adolescent, or other consenter.  
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Where 
A parent should ideally give consent in a face-to-face interview with the treating 
clinician.  Such contact will provide the best opportunity for careful consideration 
of the questions needing attention.  It is less desirable, but sometimes necessary, 
to discuss treatment recommendations and obtain consent by telephone, as when 
treatment is being provided in a residential setting and when it is difficult for 
parent and clinician to meet in person. 
To Whom 
Consent should be given to the clinician prescribing medication.  When the 
prescribing clinician cannot meet personally with the person providing consent, 
consent may be given by telephone and written note made of it, signed by the 
clinician. 
 
C. Integration of Treatment  
 
Pharmacotherapy should be coordinated with other interventions.  All 
interventions should comprise an integrated treatment plan.  Massachusetts DMH 
regulations require providers to obtain authorizations to receive and/or release 
protected health information (except for emergencies).  Authorizations must be 
signed by the person legally authorized to make health care decisions. 
 
Physicians prescribing medications for children and adolescents should speak to 
the primary care physician.  In addition, clinicians providing psychological services, 
(for instance, those helping the child or adolescent with self-understanding and 
self-management) should be aware of the psychiatric diagnoses and 
pharmacotherapy.  They should help the child or adolescent talk with the 
prescribing child psychiatrist.  Similarly, the child psychiatrist should be aware of 
psychological interventions and use other clinicians’ data in assessment and 
treatment planning. Treatment summaries should reflect each clinician’s 
awareness of the rest of the treatment. 
 
When clinicians share information and use the same language, it helps the child or 
adolescent make sense of his or her strengths and weaknesses and feel like a 
whole person.  All members of the team should use the same model for 
understanding the child or adolescent and for bringing about therapeutic change.  
Multiple autonomous practitioners working in isolation are unlikely to achieve an 
integrated view of the child or adolescent.   
 
Treatment summaries should be written so that they are understandable to 
parents and guardians and can be shared with other clinicians, including primary 
care clinicians and educators, as appropriate.   
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D. Communication and Record Keeping 
  
Treatment needs to be summarized in a concise record that is easily shared from 
one treatment setting to another, consistent with the requirements of 
confidentiality.  Authorization for the release of protected health information 
should be obtained routinely as children and adolescents enter services. 
 
A summary of a child's medication treatment must be more than a list of 
medications.  It must state whether the trial of each medicine was adequate, 
whether each medicine helped with specific symptoms, and whether the 
impression of effectiveness was clear or, as often happens, ambiguous. 
 
The parent or legal guardian of a child or adolescent, including custodial agency, 
should keep copies of all assessments and treatment summaries so that each new 
provider can review the treatment history.  Accordingly, the parent or legal 
guardian should receive all treatment records from providers promptly.  Treating 
clinicians should not prescribe new treatments until they have reviewed 
summaries of previous assessments and treatment or spoken to prior treaters 
while awaiting receipt of the records. 
 
E. Continuity of Care  
 
Although the problems for which a child or adolescent is prescribed medication are 
not short-term, many children and adolescents are cared for in multiple short-term 
placements.  Frequent movement requires that assessment and treatment 
information be efficiently transmitted from one setting to another.  The possibility 
that frequent changes of residence and caregivers may make symptoms worse 
should be considered as a factor contributing to the child’s or adolescent’s 
problems.  As the child or adolescent recovers, the goal should be to provide 
continuity of treatment, including medication, and relationships.   
 
Discontinuity of care may be a special problem for children and adolescents 
entering the custody of the Department of Social Services (DSS) or detained in a 
Department of Youth Services facility.  Clinicians prescribing psychoactive 
medications for children and adolescents should be familiar with different 
agencies’ regulations regarding the use of antipsychotic medications.  Specifically, 
if a child or adolescent is taking an antipsychotic medication without judicial 
review at the time he or she comes under DSS custody, clinicians and others 
should be alert to the risks of abruptly stopping psychoactive medication and 
appropriately advise those with responsibility for the child’s or adolescent’s care.  
The same considerations apply when children and adolescents on psychoactive 
medication enter a DYS facility.  Interruption or discontinuation of that treatment 
might cause psychological deterioration and might violate the individual’s legal 
right to treatment.   
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III. MEDICATIONS IN CURRENT USE 
 
This section lists medications in current use and their indications.  A more 
extensive discussion of the effectiveness and safety of medications commonly 
prescribed to children and adolescents has been published in the journal Child and 
Adolescent Psychiatric Clinics of North America (Pappadopulos EA, Tate Guelzow 
B, Wong C, Ortega M, Jensen PS, 2004).  That review is organized according to 
class of medications; separate articles review stimulants, antidepressants, mood 
stabilizers, antipsychotics, anti-anxiety medicines, a class of medicines called 
adrenergics and a drug that blocks the effects of opiates, called naltrexone. 
 
This section lists names only; some important information, like dose ranges, is 
excluded.  Parents and Personal Representatives should be aware of differences in 
what is called potency, that is, the therapeutic power of a medication per 
milligram.  A few milligrams of one medication may be more "potent" than 
hundreds of milligrams of another, even within the same class.  Needless to say, 
parents should not change doses on their own, hoping for a different effect, but 
must work with the prescribing clinician. 
A. Stimulants (or Psychostimulants) 
Stimulants have been used for decades to treat children who are hyperactive and 
inattentive.  These medications reduce hyperactivity and inattention and improve 
behavioral control and cognitive performance.   (These effects are similar to those 
of caffeine, another stimulant.)  Research indicates that stimulants are effective 
long-term.  Children and adolescents vary considerably in their responses to 
stimulants; many children and adolescents experience only partial symptom relief.  
(Also see atomoxetine (Strattera) below at III.E. and Attention Deficit-
Hyperactivity Disorder in section V. B.) 
 
Generic Name Brand Name 
Methylphenidate................................. Ritalin  
 Methylin 
Methylphenidate skin patch ................. Daytrana 
Dexmethylphenidate........................... Focalin 
Sustained-release methylphenidate...... Concerta  
 Ritalin SR 
 Metadate  
Sustained-release dexmethylphenidate Focalin XR 
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Dextroamphetamine ........................... Dexedrine  
 Dextrostat 
Pemoline ........................................... Cylert 
Dextroamphetamine and Amphetamine Adderal 
B. Antidepressants 
 
Antidepressant medications treat depression (and some kinds of anxiety).  They 
have been prescribed to adults for several decades and to children more recently 
(see below, in Section V. A.).  There are several classes of antidepressants, named 
for their chemical structure or for the way they are thought to work in the brain.  
The first antidepressants were called “tricyclic antidepressants.”  Medications 
introduced more recently are called “selective serotonin reuptake inhibitors 
(SSRIs)” because they are thought to act principally by changing the way the 
brain handles serotonin.  
Selective Serotonin Reuptake Inhibitors (SSRIs) 
 
Selective serotonin reuptake inhibitors (SSRIs) have been widely prescribed for 
depression and anxiety for children and adolescents.  Fluoxetine (Prozac and 
others), especially when combined when cognitive-behavioral therapy, has been 
shown to be the most effective (Vitiello, et al, 2006).  While the possibility of 
suicidal ideas or impulses, called “suicidality,” led the Food and Drug 
Administration to require a “black box” warning when antidepressants are 
prescribed for children and adolescents, there is a greater risk of suicide if 
depression goes untreated.  (The latest FDA recommendation, extending this 
warning to young adults, is at 
http://www.fda.gov/cder/drug/antidepressants/default.htm.)  
Such warnings are a reminder that all psychoactive medications should be 
prescribed only after a careful assessment, analysis of possible benefit and risk 
with and without treatment, fully informed consent (see below), and monitoring of 
the child once treatment has begun. 
Generic Name Brand Name 
Fluoxetine .................................. Prozac, Sarafem 
Sertraline ...................................................Zoloft 
Paroxetine.......................................Paxil, Pexeva 
Fluvoxamine.............................................. Luvox 
Citalopram ............................................... Celexa 
Escitalopram………………………………………….Lexapro 
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Tricyclic Antidepressants (TCAs) 
Tricyclic antidepressants (TCAs), long the most commonly prescribed 
antidepressants in adults, have repeatedly been shown to be effective in treating 
depression and anxiety in adults but not in children and adolescents.  Some TCAs 
are effective in treating other symptoms in children and adolescents, including 
Attention Deficit Hyperactivity Disorder (ADHD) symptoms and bedwetting. Side 
effects, especially potential cardiac effects and sudden death in a few children and 
adolescents on desipramine, make TCAs no longer “first-line” treatment for 
depression.   
Generic Name Brand Name 
Nortriptyline .............................. Aventyl, Pamelor  
Desipramine ........................................Norpramin  
Imipramine .............................................Tofranil  
Clomipramine ........................................ Anafranil  
Amitriptyline............................................... Elavil 
Protriptyline…………………………………….........Vivactil 
 
Monoamine Oxidase Inhibitors (MAOIs) 
Among the other antidepressants, a class of drugs called monoamine oxidase 
inhibitors (MAOIs) which block the action of an enzyme by that name.  They are 
not considered “first-line” medications for children and adolescents.  Newer MAOIs 
do not have the same side effect risks and may be used in the future to treat 
depression.  
Generic Name Brand Name 
Tranylcypromine ......................................Parnate 
Phenelzine................................................. Nardil  
 
Other Antidepressants 
Bupropion (Wellbutrin) is an antidepressant that is effective for symptoms of 
ADHD.   
Research with other antidepressants in children and adolescents has not 
demonstrated effectiveness. 
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Generic Name Brand Name 
Venlafaxine ..............................................Effexor 
Nefazodone ............................................ Serzone 
Trazodone............................................... Desyrel  
 
Bupropion ................................ Wellbutrin, Zyban 
 
Mirtazapine ...........................................Remeron 
 
     Duloxetine ........................................... Cymbalta 
 
C. Mood Stabilizers 
Mood stabilizers have been shown to be effective in the treatment of bipolar 
disorder (also called manic-depressive disorder) in adults.  Their use in children 
and adolescents is controversial (see Section VI., Areas of Controversy). Some 
studies have suggested an association of weight gain and endocrine side effects 
(polycystic ovary syndrome) with valproate use in women. 
Generic Name Brand Name 
Lithium ......................Eskalith, Lithonate, Lithobid 
Carbamazepine.........................Tegretol, Carbitrol 
Valproate ............................................. Depakote  
Gabapentin ..........................................Neurontin  
Lamotrigine ............................................Lamictal  
Topiramate........................................... Topamax  
Oxcarbazepine........................................ Trileptal 
 
Another class of mood stabilizers, omega-3 fatty acids, is beginning to be used 
together with other mood stabilizers in adults.  They may be used in the future in 
children and adolescents. 
D. Antipsychotics 
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Antipsychotic medications reduce psychotic symptoms in children and adolescents 
with schizophrenia and other psychotic disorders, reduce verbal and motor tics in 
children and adolescents with Tourette Syndrome, and reduce manic symptoms in 
adults and children and adolescents.  They may also have a role in reducing 
certain abnormal behaviors in children and adolescents with autism and mental 
retardation.   
 
There are two classes of antipsychotic medications.  The older medications 
(chlorpromazine and others) are called “first-generation antipsychotics” (FGAs).  
The newer medications, like risperidone, are called “second-generation 
antipsychotics.”  (They are also called “atypicals,” because they came later.) 
 
First-generation antipsychotics (like chlorpromazine) carry significant risk of 
movement disorders in both the short and long term.  Second-generation 
medications (like risperidone) cause movement disorders but probably with less 
frequency; of more concern is their association with serious metabolic risks, 
including serious weight gain, development of diabetes mellitus, and abnormal 
secretion of a hormone called prolactin.  Weight gain is especially pronounced 
with olanzapine (Zyprexa) and clozapine (Clozaril).  The most effective second-
generation medication, clozapine (Clozaril), also carries a small but definite risk of 
bone marrow suppression.  Patients on clozapine must have a blood test every 
other week.  Quetiapine (Seroquel) can cause cataracts in adults; children and 
adolescents on this medication should have regular ophthalmologic exams.  All 
antipsychotics can be sedating, sometimes to a degree that interferes with optimal 
functioning. 
First-generation Antipsychotics: 
Generic Name Brand Name 
Chlorpromazine ....................................Thorazine 
Haloperidol................................................Haldol  
Perphenazine...........................................Trilafon  
Fluphenazine ........................................... Prolixin  
Pimozide .....................................................Orap  
Thiothixene ............................................. Navane  
Molindone ................................................ Moban  
Loxapine ................................................Loxitane  
Droperidol ............................................. Inapsine 
Thioridazine .............................................Mellaril 
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Second-generation Antipsychotics (also known as “atypical” 
Antipsychotics): 
Generic Name Brand Name 
Risperidone ...........................................Risperdal 
Olanzapine ............................................. Zyprexa 
Clozapine ................................................ Clozaril 
Quetiapine ............................................ Seroquel  
Ziprasidone .............................................Geodon 
Aripiprazole…………………………………………...Abilify 
Paliperidone…………………………………………..Invega 
 
In Massachusetts, the prescription of antipsychotic medication is considered 
“extraordinary treatment.”  Parents can authorize such treatments, but the 
Department of Social Services does not authorize such treatment for children and 
adolescents in its custody.  For such children and adolescents, a court order (in 
response to a Rogers petition) is required (see “Informed Consent,” in section 
IV.B.4). 
 
E. Other Medications 
 
A few other medications are currently used in children and adolescents, primarily 
for the treatment of anxiety and/or impulse control problems.  They include the 
medications listed below. 
 
Benzodiazepines  
 
Benzodiazepines are used to treat anxiety symptoms and sleep problems in adults; 
research has provided some support for their use in children and adolescents.  
People taking these medicines long-term may develop problems with tolerance, 
dependence, and habituation.  These medicines are also subject to non-medical 
use, which can cause undue sleepiness or intoxication, especially when combined 
with alcohol.  Some people taking benzodiazepines develop disinhibited behavior 
or hallucinations.  Withdrawal from benzodiazepines can be difficult.   
 
Generic Name  Brand Name  
 
Clonazepam .......................................... Klonopin  
Lorazepam ................................................Ativan 
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Alprazolam ................................................ Xanax  
 
Others  
Buspirone.................................................Buspar  
Clonidine............................................... Catapres  
Guanfacine................................................ Tenex  
Naltrexone .................................................Revia 
Atomoxetine………………………………………….Strattera  
Propanolol……………………………………………….Inderal 
 
Buspirone can be effective in treating anxiety in adults, with relatively few side 
effects.  There are no controlled studies with children and adolescents.  Clonidine 
has long been used to treat high blood pressure in adults.  It has been used 
extensively with children and adolescents for treating tics, ADHD, aggressive 
behavior, and sleep problems.  Research support for its use in these disorders is 
mixed.  Guanfacine (Tenex) is a newer medication, similar to clonidine but longer-
acting, less sedating, and possibly more effective in improving attention.  It is 
used in treating impulsiveness and hyperactivity associated with ADHD and other 
disorders. Research has not demonstrated its effectiveness.   
 
Atomoxetine (Strattera) is a non-stimulant medication for treatment of ADHD. 
 
Naltrexone (Revia), an opiate antagonist, is used to treat self-injurious behavior.  
Beta-blockers like propanolol (Inderal) are used to treat anxiety, especially 
performance anxiety, and aggressive behavior.  
 
V. AREAS OF CONTROVERSY 
 
In some areas, child psychiatrists are still working to achieve consensus. In other 
areas, public opinion is divided.  Parents, guardians, and children and adolescents 
should be aware that different practitioners may approach the same problem 
differently.  
 
A. Use of Antidepressants in Children and Adolescents 
 
The treatment of depression in children and adolescents is changing.  Depression 
is a serious problem in children and adolescents, as emphasized in the Surgeon 
General's report.  Depression causes suffering, prevents children from 
participating in school, and puts children at risk of suicide.  More depressed 
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children are getting help, as parents and professionals have recognized that young 
people get depression and, when depressed, can benefit from treatment.  
However, most depressed children and adolescents, like most adults with 
depression, still do not receive help.  Help begins with adults letting a child know 
they recognize his or her distress and that they do not blame him or her.   
 
What help to offer is increasingly clear.  Evidence now indicates that 
antidepressant medication, the so-called SSRIs, can help depressed adolescents, 
especially when combined with a psychological treatment, cognitive-behavior 
therapy.  While a few depressed children develop suicidal ideas or impulses while 
taking SSRIs (mentioned in the “black box warning” from the FDA), it seems that 
suicides may have increased after the FDA posted a warning and SSRI use 
decreased. Others point out the great variability in responses to these medicines; 
even if the many do not respond, many individuals may benefit.  
 
The use of antidepressants in children and adolescents, even more than with 
other medications, requires careful weighing of potential risks and benefits with 
and without treatment.  Prescription of antidepressants requires careful 
assessment of these risks and informed decision-making. 
 
The Department of Mental Health urges families and caregivers with young people 
taking or considering taking antidepressant medication to keep in mind the 
following good practices: 
 
• Monitoring of the patient by physicians, families and caregivers 
• Not abruptly stopping medications without medical advice 
• Positive and ongoing communication with the prescribing physician 
• Careful risk/benefit analysis when considering antidepressants for young 
people, including providing information and allowing time for questions and 
answers from the patient, family and caregivers 
• Review of the patient information sheet (“Medication Guide”) from the FDA  
 
Also see discussion of "antidepressant activation" in Section C, below. 
 
B.    Attention Deficit-Hyperactivity Disorder  
 
Attention Deficit-Hyperactivity Disorder, although one of the most studied 
disorders in child psychiatry, is often misunderstood.  Typical ADHD symptoms in 
school-age children and adolescents (restlessness, distractibility, poor attention) 
resemble the normal behavior of younger children.  Controversy exists as to the 
diagnosis of ADHD and the use of stimulants in children under five years of age.  
Moreover, considerable misleading and inaccurate information about ADHD and 
stimulant therapy has been distributed, some of it coming from groups opposed to 
all treatments in psychiatry.  Nonetheless, ADHD is different from normal 
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behavior.  Children and adolescents with ADHD are at increased risk for academic, 
social, and legal problems.  A consensus statement developed by the National 
Institutes of Health concluded that ADHD is a valid disorder with considerable 
costs to individuals and society.  Effective treatments exist for ADHD, stimulants 
being more effective than psychosocial treatments.  There is no known prevention 
for ADHD.   
 
Stimulant medication helps children and adolescents with ADHD to concentrate 
and focus better.  Stimulant medication is as good as or better than behavioral 
treatment alone. Options in treating ADHD have increased with the demonstration 
that clonidine (Catapres) and guanfacine (Tenex), alpha-adrenergic agonists, in 
addition to the stimulants, can be effective, especially for hyperactivity, and with 
the introduction of a non-stimulant medication (atomoxetine (Strattera)). 
 
Despite this evidence, many children and adolescents with ADHD get no 
treatment.  The Surgeon General (1999) reports that, while ADHD occurs in three 
to five percent of school-age children, only two to three percent of school-aged 
children are being treated for ADHD. 
 
MEDICATIONS USED IN ATTENTION DEFICIT-HYPERACTIVITY DISORDER  
 
STIMULANTS 
 
Short-acting: 
 
Methylphenidate (Ritalin) 
Desxmethylphenidate (Focalin)  
Dextroamphetamine (Dexedrine) 
Pemoline (Cylert) 
 
Intermediate-acting: 
 
Sustained-Release Methylphenidate (Metadate ER) 
Methylin ER  
Ritalin SR 
FocalinXR 
Daytrana patch 
 
Long-acting: 
 
Concerta 
Sustained-Release Methylphenidate (Metadate CD) 
Dexedrine Spansules 
Amphetamine Mixture (Adderall XR) 
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ALPHA-ADRENERGIC MEDICATIONS 
 
Clonidine (Catapres) 
Guanfacine (Tenex) 
 
ANTIDEPRESSANTS 
 
SSRIs, TCAs, Bupropion (Wellbutrin)   
 
OTHER 
 
Atomoxetine (Strattera) 
 
Several points bear emphasis.  First, children and adolescents with ADHD tend to 
have other problems as well.  Accordingly, those treating children and adolescents 
with ADHD may make several diagnoses and recommend more than one 
medicine.  Second, several factors other than ADHD may make it hard to 
concentrate.  The child or adolescent who is hungry, or who is worried about his 
or her safety, or who has flashbacks or thought disorganization, or whose school 
program does not match his or her needs, will have difficult attending to 
schoolwork.  Amid such possibilities, the possibility of ADHD must be considered in 
the context of an overall assessment of the child and his or her life situation.  
Third, the benefit of stimulant medication may only become apparent when 
external and internal turmoil has subsided.  That is, a child or adolescent may 
benefit from stimulants, but not while being abused or neglected or while 
struggling to learn in when no one knows he has a learning disability, or while in 
an acute psychotic state.  The child or adolescent who does not appear to benefit 
from stimulants at such a time may, when the other problems improve, benefit.  
Medication treatment for ADHD should not be undertaken as if the other problems 
did not exist. Fourth, in a child or adolescent receiving multiple medications, the 
interaction between the medications must be carefully monitored. 
 
With ADHD as with other disorders, different clinicians, even with the same data, 
may make different treatment recommendations. 
 
C. Bipolar Disorder 
 
Recent research indicates that bipolar disorder occurs in children and adolescents.  
Its features include emotional lability, especially tantruming, as well as 
hypersexuality and suicidal behavior.  Treatment with mood stabilizers may be 
helpful.  Clinicians disagree about the criteria for this diagnosis in children and 
adolescents and whether to recommend treatment with mood stabilizers.  A family 
history of bipolar disorder in a child or adolescent presenting with serious 
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problems with mood or temper regulation warrants close monitoring of any 
antidepressant use and a possible trial of a mood stabilizer.  Inappropriate 
diagnosis of bipolar disorder, on the other hand, may expose the child or 
adolescent to unwarranted medication and undercut the child or adolescent’s 
efforts at self-understanding and self-management.  When a child or adolescent, 
or the family, say, “I’m (he’s) bipolar-” they may stop thinking about the course, 
meaning, and management of mood changes or emotional dysregulation. 
 
Related to bipolar symptoms is so-called “antidepressant activation.” This term is 
used when the child or adolescent taking an antidepressant develops increased 
activity, irritability, insomnia, hypersexuality, grandiosity, hallucinations or rapid 
talking.  Such activation does not make the diagnosis of bipolar disorder nor 
predict its emergence later; it may just be a medication side effect unrelated to 
bipolar disorder.  Some children and adolescents may benefit from antidepressant 
medication but only when also taking a mood stabilizer.  For such children and 
adolescents, a mood stabilizer may be prescribed along with an antidepressant. 
 
D. Use of Antipsychotics (also known as Neuroleptics) 
 
Some clinicians prescribe antipsychotic medications only for frank psychotic 
thought disorder.  Others argue for a broader range of use in children and 
adolescents, helping those with severe, confusion or uncontrollable emotional 
flooding.  Both first- and second-generation antipsychotics have serious effects.  
Their prescription is not to be undertaken lightly. 
 
Antipsychotic medications should not be prescribed for children and adolescents as 
a substitute for acknowledging and treating their other challenges.  Many 
challenges—such as unrecognized abuse or molestation, post-traumatic states, 
severe caretaking deficits, unrecognized visual or hearing impairment or other 
learning disability, or unacknowledged family conflict—can make children and 
adolescents feel overwhelmed and disorganized.  Too hasty assessment of such 
children and adolescents can result in injudicious prescription of possibly 
unwarranted medication, as well as delay in recognizing and addressing other 
adversities in the life of the child or adolescent. 
 
On the other hand, when the efforts of the child or adolescent to cope with 
adversity are compounded by inner disorganization, environmental interventions 
may still leave them too disorganized to take advantage of the opportunities 
available.  A trial of antipsychotic medication may dramatically enhance such 
individuals’ ability to cope.  
 
A comprehensive plan must ascertain that antipsychotic medication, if offered, has 
indeed made a difference in the child’s or adolescent’s coping and that such use is 
continued no longer than necessary. 
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E.  Post-Traumatic States  
 
While we know much about post-traumatic symptoms in children and adolescents, 
researchers are still evaluating what are the best treatments for traumatized 
children and adolescents.  It is important to differentiate between “simple PTSD” 
which follows a discrete traumatic event, and “complex PTSD,” which follows 
multiple traumas, over time, often not acknowledged, and associated with a wide 
variety of symptoms.  Treatment options include psychotherapy, especially 
cognitive-behavior therapies (CBT), pharmacotherapy and the newer physical 
therapies such as eye-movement desensitization and reprocessing (EMDR).  
Medications like clonidine and the SSRIs (fluoxetine, etc) help children and 
adolescents cope with the symptoms that come from trauma.  The use of such 
medications in children and adolescents rests on clinical experience, not on 
controlled clinical research trials.   
 
Abused and neglected children and adolescents often present with extreme 
fragility, withdrawal, aggression and mood instability that do not meet full criteria 
for PTSD but that require intervention.  Treatment for such children and 
adolescents should include protective intervention, protective acknowledgement, 
and psychological support by experienced therapists.  Interventions should not be 
limited to the use of medications, nor should diagnoses with lasting significance be 
made while the trauma-surviving child is just emerging from an unprotective 
traumatic environment. 
 
Symptoms such as “hearing voices” are often present in traumatized children and 
adolescents.  Such hallucinosis is not in itself an indicator of psychotic illness and 
may not require anti-psychotic medications, with the attendant risks.  Children and 
adolescents with a history of trauma may also respond to subtle reminders of the 
trauma with behavioral outbursts and emotional instability resembling that seen in 
affective disorders.  Mood stabilizers, which are accompanied by fewer risks than 
antipsychotics, may be helpful in treating such children and adolescents.   
 
A thorough assessment of the child or adolescent, noting current and past trauma, 
is necessary to identify factors that may respond to medications, as well as those 
that require psychotherapy and environmental interventions.   
F. Children and Adolescents with Developmental Disabilities  
 
Psychiatric symptoms in children and adolescents with developmental disabilities 
present many clinical challenges, including whether to use medication.2  It is 
                                                 
2 Identifying sources of help for children with developmental disorders, including autism and 
Asperger’s syndrome, can be confusing.  Federal regulations locate responsibility for such children, 
including their mental health problems, in the public schools (the so-called Local Education 
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unclear which diagnostic criteria should be used in this population, especially in 
children and adolescents with IQ’s below 50.  Diagnostic uncertainty 
notwithstanding, children and adolescents with developmental disabilities are 
more likely to have multiple disorders.   
 
Developmentally delayed children and adolescents with psychiatric symptoms 
should have a thorough assessment in a multidisciplinary setting and should be 
offered comprehensive therapy with emphasis on specialized behavioral 
interventions. 
 
We do not know enough about the safety and effectiveness of psychoactive 
medications in children and adolescents with developmental disabilities; there are 
only a small number of sound studies.  Many medications have been 
recommended; few have been shown to be effective in controlled trials.  
Nevertheless, depending on the circumstances of the individual child or adolescent 
(and possible associated psychiatric comorbidity), antipsychotics or mood 
stabilizers may be recommended.  A recent well-designed study demonstrated a 
positive response to risperidone (Risperdal) in children with developmental 
disorders. 
 
Pharmacological intervention is often recommended when aggressive or self-
injuring behavior is so intense, frequent or persistent as to threaten the child or 
adolescent or those nearby.  It may also be recommended when behavior is so 
disruptive that the child or adolescent cannot use school or occupational, physical, 
speech, or interactional therapies.  Except in emergencies (see below, Section G), 
clinicians should not prescribe something immediately “to take the edge off” the 
challenging behaviors in lieu of a diagnostic assessment that will complete the 
overall picture of the child or adolescent, including delineation of the factors that 
contribute to the behavior. Parents, teachers, and other caregivers may need 
considerable support during this phase, in order to ensure their cooperation with 
the recommended treatment plan. 
 
It is advisable to treat each case on an individual basis, “as a single case study, 
starting with the safest and most commonly used medications in low doses and 
increasing the dose gradually” (Santosh & Baird, 1999).  In deciding to continue 
treatment or revise the plan, adults should use reports of behavioral changes, 
including the child's own assessment, the child’s tolerance for side effects, and 
any idiosyncratic reactions to the medication.   
 
           
                                                                                                                                                    
Authority).  In Massachusetts, developmentally disabled people over age 22 are served by the 
Department of Mental Retardation.  In this booklet, we address the principles that guide their 
medication treatment, not where services are to be found. 
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G. Extreme Behavioral Loss of Control (Aggressive and  
 Self-Injurious) 
 
As mentioned above, medication treatment in children and adolescents is based 
more on clinical experience than on controlled clinical trials—especially when 
dealing with children and adolescents with aggressive or self-harming behavior.   
For many such children and adolescents, the need for urgent intervention is often 
clearer than the diagnosis.  With or without diagnostic clarity, medication is often 
an important part of their treatment.  Such treatment must, like any treatment, be 
part of a carefully developed plan based on comprehensive assessment.  When 
the diagnosis is uncertain, specifying the factors that contribute to the problem 
may help to summarize a formulation and guide treatment.  Target symptoms 
should be identified, as in any other treatment, and medications judiciously 
introduced, with the results monitored according to an agreed-upon plan. 
 
It is essential to examine the context in which aggressive or self-harm behavior is 
occurring.  Medication should never be prescribed for a child or adolescent with 
extreme behavioral loss of control without an inquiry into context and interactions.  
Assessment should also be alert to the possibility of undiagnosed medical disorder 
(endocrine-metabolic or toxic), of substance use including caffeine or withdrawal 
from nicotine, and of unrecognized psychiatric disorder, such as post-traumatic or 
other anxiety disorder, depression or bipolar disorder, or unrecognized psychosis. 
 
In prescribing any agent for extreme behavioral loss of control, the clinician 
should balance the urgency of the situation against the desirability of acquiring 
more understanding before taking action.  The clinician should also consider 
whether the treatment will constitute an emergency, and, if so, whether treatment 
will be voluntary or involuntary (see Section H, below). 
 
In general, pharmacological treatment of extreme behavioral loss of control starts 
with less toxic, shorter-acting medications: sedatives (like diphenhydramine 
[Benadryl and others]), alpha-agonists and beta-blockers.  Longer-acting 
medications and those with more side effects (mood stabilizers, antidepressants, 
naltrexone [Revia], antipsychotics) are recommended either when a specific 
disorder is diagnosed (e.g., depression, bipolar disorder, or psychosis) or as an 
empirical trial when shorter-acting or less toxic medications have failed or are 
deemed unlikely to be effective. 
 
H. Involuntary Treatment 
 
This guideline may give the impression that medication treatment is always 
voluntary, but involuntary treatment also occurs.   
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A competent child or adolescent or parent/guardian has the right to refuse 
treatment.  Therefore, involuntary treatment may be given only when a court has 
found the parent/guardian to be incompetent to provide informed consent or that 
the parent/guardian is endangering the child or adolescent, as in a life-threatening 
situation.   
 
When a parent/guardian gives informed consent for treatment and the minor child 
refuses treatment, it is incumbent upon the treating clinician to attempt to gain 
the minor’s assent (although there is no legal obligation to do so).  If a parent or 
legal guardian refuses to consent to treatment and a clinician judges that this 
refusal places the well-being of the child or adolescent in jeopardy, the clinician 
should consider seeking assistance from the Department of Social Services or 
asking the court to appoint a new guardian.    
 
Emergency involuntary medication treatment may be given in two contexts.  In 
one setting, chemical restraint medication is given involuntarily to assist in 
containing a child with immediately threatening behavior.  At other times, 
emergency involuntary medication may be given to prevent immediate, substantial 
and irreversible deterioration of serious mental illness. 
 
Chemical restraint, like all forms of restraint, may only be used in emergencies, 
when extreme violence, personal injury, or attempted suicide has occurred or 
been threatened.  Such measures can be used only when there is a substantial 
risk of serious self-destructive behavior or of serious physical assault or when a 
serious physical assault has occurred.  A child or adolescent may be given 
chemical restraint only on the order of an authorized physician.  This physician 
must have determined that such chemical restraint is the least restrictive, most 
appropriate alternative available.  The physician can make this determination while 
present in person or after telephone consultation with a physician, registered 
nurse or certified physician assistant who was present at the time of the 
emergency and who personally examined the child or adolescent (See DMH 
Regulations 104 CMR 27.12).   [In schools, the Department of Education regulates 
the use of restraint and requires authorization by a physician and parent.]   
 
Apart from situations requiring use of restraint, emergency treatment occurs very 
infrequently.  It may occur only when the physician believes that delaying 
treatment in order to obtain a court order for the treatment poses the risk of the 
substantial and irreversible deterioration of the child or adolescent’s serious 
mental illness.  There are very few instances in which this threshold is met.   
 
I. Adverse Side Effects  
 
All prescribing child psychiatrists and other clinicians are concerned about possible 
adverse side effects of medication.  Opinions differ as to how to weigh the 
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advantages and disadvantages of a course of treatment in a given child or 
adolescent. The final decision, of course, rests with the parent or guardian, with 
the advice of clinicians.  Once treatment is underway, vigilance is indicated for 
emergent side effects, including unusual or idiosyncratic reactions.  For instance, 
mood stabilizers/anticonvulsants like valproate (Depakote and others), which help 
most children to manage emotional lability, may cause increased irritability and 
temper tantrums in some.   
   
Of particular concern are the metabolic side effects of second-generation 
antipsychotics (see above, II. D.). The American Psychiatric Association and 
American Diabetes Association (2004) have made recommendations for the use 
and monitoring of these medications. 
 
 
VI.   CLIENT/PARENT EDUCATION  
 
Parents, full of questions as they seek the best care for their children, confront an 
unprecedented volume of information, including on the internet, of varying 
quality.  There is no substitute, in this flood of information, for personal 
relationships with trusted providers (primary care physicians, social workers, or 
child psychiatrists).  In addition to those personal resources, the following books, 
articles, and websites are recommended: 
 
Connor DF, Meltzer BM.  Pediatric Psychopharmacology:  Fast Facts.  New York:  
WW Norton, 2006. 
 
Dulcan MK ed.  Helping Parents, Youth, and Teachers Understand Medications for 
Behavioral and Emotional Problems.  A Resource Book of Medication Information 
Handouts.  Washington DC:  American Psychiatric Press, 1999. 
 
Findling RL, Steiner H, Weller EB.  Use of antipsychotics in children and 
adolescents.  J Clin Psychiatry 2005; 66 Suppl 7:29-40. Review. 
 
Greene RW. The Explosive Child: A new approach for understanding and parenting 
easily frustrated, “chronically inflexible” children.  New York: Harper Collins, 1998 
 
McClellan J, Kowatch R, Findling RL; AACAP Work Group on Quality Issues. 
Practice parameter for the assessment and treatment of children and adolescents 
with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:107-125.  
 
National Institute of Mental Health – Health Information  
http://www.nimh.nih.gov/ 
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US Public Health Service.  Report of the Surgeon General’s Conference on 
Children’s Mental Health: A National Action Agenda.  Washington DC:  Department 
of Health and Human Services, 2000.  Also available at 
http://surgeongeneral.gov/cmh/childreport.htm 
 
Vitiello B, Rohde P, Silva S, Wells K, Casat C, Waslick B, Simons A, Reinecke M, 
Weller E, Kratochvil C, Walkup J, Pathak S, Robins M, March J; TADS Team.  
Functioning and quality of life in the Treatment for Adolescents with Depression 
Study (TADS).  J Am Acad Child Adolesc Psychiatry 2006; 45:1419-26. 
 
Wilens TE. Straight Talk about Psychiatric Medications for Kids.  New York:  
Guilford Press, 1999. 
 
www.aacap.org – American Academy of Child and Adolescent Psychiatry – Facts 
for Families 
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